Clinical Summary: Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study
Acute bipolar mania often requires rapid symptom control, yet many patients do not find a treatment option they can both tolerate and stay on. This study addresses whether iloperidone can reduce manic symptoms in adults with bipolar I disorder while maintaining the relatively favorable akathisia and extrapyramidal side effect profile that can influence antipsychotic selection.
Key Findings
- Change in YMRS total score from baseline to week 4 was statistically significant for iloperidone compared with placebo, with statistically significant difference between iloperidone and placebo observed on days 14, 21, and 28.
- At day 28, statistically significant differences between iloperidone and placebo were seen on CGI-S, CGI-C, and YMRS responders, but change from baseline in MADRS did not achieve statistical significance.
- At least 1 adverse event occurred in 67.5% of iloperidone-treated patients versus 48.6% of placebo-treated patients; TEAEs leading to study drug discontinuation occurred in 18 (8.7%) patients on iloperidone versus 11 (5.3%) on placebo.
- Common adverse events with iloperidone were tachycardia 17.5% (36/206 patients), dizziness 11.2% (23/206 patients), dry mouth 9.2% (19/206), alanine aminotransferase increased 7.3% (15/206 patients), nasal congestion 6.3% (13/206), increased weight 5.8% (12/206 patients), and somnolence 5.3% (11/206 patients).
- Mean weight increase (SD) was 4.60 ± 4.271 kg with iloperidone versus 1.63 ± 3.578 kg with placebo; mean QTcF change from baseline to day 28 was +8.3 msec with iloperidone versus −1.0 msec with placebo, and post-randomization QTcF increases of ≥ 60 msec occurred in 3 iloperidone patients and 0 placebo patients.
Iloperidone improved acute manic symptoms in adults with bipolar I disorder by 4 weeks, with separation from placebo beginning at day 14. Its use requires the same practical tradeoff seen with many second-generation antipsychotics: meaningful antimanic benefit alongside monitoring for weight gain, tachycardia, orthostatic effects during titration, and QTcF prolongation.
Practice Implications
- Do not expect a clear antimanic efficacy signal in the first week; in this study, statistically significant separation from placebo on YMRS was observed on days 14, 21, and 28.
- Monitor blood pressure closely during titration, when orthostatic response was more frequent with iloperidone, and recognize that rates were 5.6% with iloperidone and 4.5% with placebo at week 4.
- Check weight and discuss metabolic burden early, because mean weight increase (SD) was 4.60 ± 4.271 kg with iloperidone versus 1.63 ± 3.578 kg with placebo over 28 days.
- Use ECG and medication review when prescribing iloperidone, especially given mean QTcF change of +8.3 msec, 3 patients with post-randomization QTcF increases of ≥ 60 msec, and the protocol’s dose reduction to 12 mg/d (6 mg twice daily) in CYP2D6 poor metabolizers.
